N/A
N=84
Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control
Dry Eye Syndromes
Bottom Line
View on ClinicalTrials.gov: NCT03325673 ↗Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye — 15.3; 17.2 score on a scale — p=0.116
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- TrueTear (Device); TrueTear Sham Control (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye |
15.3; 17.2 | 0.116 |
| PRIMARY Comfort Rating Score in the Study Eye |
88; 86; 86; 82; 75; 69 | 0.468 |
| PRIMARY Comfortable Wear Time (CWT) in the Study Eye |
618; 574 | 0.488 |
| PRIMARY Total Wear Time (Total WT) in the Study Eye |
747; 652 | 0.072 |
Summary
This study will evaluate the increase in comfort and comfortable contact lens (CL) wear time associated with application of TrueTear (active intranasal neurostimulation) compared with application of TrueTear sham control (intranasal application which is not electrically active) in symptomatic CL wearers.
Eligibility Criteria
Inclusion Criteria
A person is eligible for inclusion if he/she
- In at least one eye, has a cotton swab nasal stimulation Schirmer test score at least 4 mm greater than 3 minute Schirmer with anesthesia basal score in the same eye at the Screening Visit
- Is an adapted soft contact lens wearer and currently wears lenses an average of at least 2 days per week, with an average minimum wearing time of 3 hours each day over the past month and is able and willing to wear lenses for at least 6 hours on four study day visits
- Has at least 20/40 visual acuity in both eyes with CL correction
- Is symptomatic according to Young's categorization
Exclusion Criteria
- Refractive error surgery
- Chronic or recurrent epistaxis, coagulation disorders or other conditions that may increase the risk of bleeding
- History of nasal or sinus surgery
- Vascularized polyp, deviated septum or severe nasal airway obstruction at the Screening visit
- Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head
Data sourced from ClinicalTrials.gov (NCT03325673). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.